Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
The Global Breast Lesion Localization Market Size is projected to grow at a CAGR of 5.9% from 2026 to 2032, according to a new report published by Verified Market Research®. The report reveals that ...
Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...
MoneyWeek on MSN1d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...
Zacks Research lowered its Q3 2026 earnings estimate for Vertex Pharmaceuticals from $4.15 to $4.13 per share. Other analysts ...
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
The stock's fall snapped a four-day winning streak.
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
The rising prevalence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer is greatly boosting the demand for biosensors, as these conditions necessitate frequent monitoring ...
DelveInsight's Biosensors Market Insights report provides the current and forecast market analysis, individual leading ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback